A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
Safety, Tolerability and Pharmacokinetics Study of Multiple Rising Subcutaneous Doses of Survodutide in Chinese Participants With Overweight or Obesity (BMI 24.0 to 40.0 kg/m2) (Non-randomization, Open Label, Parallel Group Design)
Sponsor: Boehringer Ingelheim
This PHASE1 trial investigates Obesity and Overweight and is currently completed. Boehringer Ingelheim leads this study, which shows 8 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Dec 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 3 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .